China's Artificial Heart Breakthrough: Suzhou CH Biomedical Advances Toward Sci-Tech Innovation Board IPO with Global Ambitions

On December 26, 2025, the STAR Market IPO application of BrioHealth Solutions (Suzhou) was accepted by the Shanghai Stock Exchange. Founded in 2008, this company has long focused on the research and commercialization of fully magnetically levitated artificial hearts and has established a business system covering mainstream markets worldwide.

BrioHealth Solutions this timeThe IPO is regarded as a significant landmark event in China's high-end active implantable medical device field. Behind it lies not only the growth story of a single enterprise but also reflects China's leap from being a follower to a competitor in heart failure treatment technology, which is known as the "cancer" of the cardiovascular field.

FillFill the gap in China, constructBuild Global Competitiveness

As the only effective means for large-scale treatment of end-stage heart failure, artificial hearts have long been characterized by extremely high technical barriers.

Globally, the full magnetic levitation technology is widely recognized as the mainstream technological pathway due to its superior clinical outcomes, and the relevant market is primarily dominated by Abbott of the United States.HeartMate 3 Dominates.

Independently Developed by BrioHealth SolutionsCH-VAD (CiFu® VAD) broke this situation. The product entered China's Innovative Medical Device Special Approval Process in 2016, and completed the first human implantation in 2017, pioneering the clinical application of implantable artificial hearts in China.

In November 2021, CH-VAD received approval from the National Medical Products Administration (NMPA) for marketing in China, becoming the first approved full magnetic levitation artificial heart product with complete independent intellectual property rights in China. The first patient implanted with the device successfully transitioned to a heart transplant after living with the artificial heart for seven years.

CH-VAD has its unique technical advantages: through an innovative discrete magnetic levitation structure and optimized hydrodynamic design, it ensures efficient blood pumping whileMinimize Blood Cell Damage to the Greatest Extent, thereby significantly reducing the incidence of complications such as thrombosis and stroke.

Meanwhile, the product features the world's thinnest (diameter3.3 mm) percutaneous cable design reduces the risk of infection. As of the date of the prospectus signing, CH-VAD has completed over 670 clinical implants in more than 80 hospitals across China.

Advance into the highest regulatory pathway in the U.S., rapidly expand global clinical trials

While making steady progress in the Chinese market,BrioHealth Solutions Takes the Global Market as Its Long-term Development Direction. Its internationalization strategy has achieved substantial breakthroughs in recent years.

In 2024, BrioHealth Solutions' new-generation implantable full magnetic levitation left ventricular assist system, BrioVAD, received FDA approval in the United States to conduct a PMA (Premarket Approval) clinical trial.This is the first time that an active implantable medical device from China has entered a clinical trial under the highest regulatory pathway in the United States.

It is worth mentioning that,The clinical trial of BrioVAD, named "INNOVATE," is conducting a "head-to-head" comparative study with Abbott's HeartMate 3, the leading product in the fully magnetically levitated artificial heart field.

This prospective multicenter study aims to rigorously validateClinical outcomes of BrioVAD in terms of hemocompatibility, hemodynamics, and portability.

The trial is proceeding rapidly, sinceSince its launch at the end of 2024, it has successfully completed the enrollment of 100 patients in just one year.

In August 2025, after successfully completing the clinical safety phase study, BrioVAD received FDA approval to enter the confirmatory phase, with the number of research centers expanding to 60 and a planned cumulative enrollment of 780 subjects.

This clinical trial has been covered by Medicare, with an average reimbursement of approximately$220,000.

The Dual Drive of Huge Demand and Supply Gap for Heart Failure Patients

BrioHealth Solutions is in a sector facing a huge unmet medical need.

Heart failure is known as"Cancer". According to statistics from the World Health Organization, there are over 60 million patients worldwide suffering from heart failure. Once diagnosed with heart failure, the 5-year mortality rate is as high as 50%, which is comparable to the survival rate of malignant tumors.

Although heart transplantation is an effective treatment for end-stage heart failure, it is limited by the availability of donors, allowing only about8,000 transplant surgeries. This number, compared to the large patient population, represents a significant gap.

In China, this contradiction is equally prominent. According to statistics,In 2023, China completed 994 heart transplants, an increase of 269 cases compared to 2022, achieving a "dual improvement in quantity and quality." However, the supply-demand contradiction remains significant when compared to the number of newly added heart failure patients each year.

In the face of such a severe imbalance between supply and demand, implantable left ventricular assist devices, namely"Artificial heart" has become the only realistic means for large-scale treatment of end-stage heart failure.

The market's growth potential is also reflected in the data. According to industry reports,The global artificial heart implant market size is expected to reach 98.415 billion RMB by 2025, with China's market at 28.255 billion RMB. By 2032, the global market size is projected to grow to 233.511 billion RMB, with an annual compound growth rate of 13.14%.

Another report predicts that the global sales of artificial hearts and ventricular assist devices willIt will reach 33.34 billion yuan in 2031, with a compound annual growth rate of 10.4%.

Under the Full Magnetic Levitation Technology Route, Chinese Enterprises Emerge

The global artificial heart market is characterized by high technological barriers and a high degree of concentration.

For a long time, Abbott (through acquisitionThoratec) has gained a dominant position in the global market with its HeartMate series, particularly the HeartMate 3, which utilizes full magnetic levitation technology.

Other internationally renowned companies include Medtronic (which once acquiredHeartWare, Berlin Heart, and CARMAT, which focuses on the total artificial heart, etc.

These enterprises have diverse product technology routes, undergoing iterations from the early pulsatile (first generation), axial flow (second generation), to suspension (third generation). Among them, the third-generation technology represented by full magnetic suspension is regarded as the mainstream direction due to its better blood compatibility and lesser damage to blood cells.

Against this technological backdrop, BrioHealth SolutionsAs one of only two globally (the other being Abbott's HeartMate 3) full magnetically levitated artificial heart products approved by relevant regulatory authorities and widely recognized by the international academic community, CH-VAD holds a technological position with significant international competitiveness.

In the Chinese market, multiple companies have actively entered the artificial heart sector in recent years. Apart from BrioHealth Solutions, other companies such as Aerospace Taisin, Eternal Heart Medical, and Shenzhen Core Medical are also engaged in the research and development or commercialization of related products.

It is worth mentioning that another enterprise engaged in the research, development, and production of artificial heart products in China"Eternal Heart Medical," whose products originated from Japanese technology. In contrast, BrioHealth Solutions has embarked on a path of independent innovation from the very beginning.

The Key Step from Technical Validation to Commercial Scaling

BrioHealth Solutions' prospectus data shows that the company's product sales revenue has shown a rapid growth trend: fromIncreased from 8.272 million yuan in 2022 to 67.0598 million yuan in 2024.

Despite the relatively small initial base, the steep growth slope reflects a rapidly increasing market acceptance of the product. AsThe advancement of the IPO process, if successfully listed, will provide more sufficient financial support for its global commercialization layout.

The progress of its international clinical trials, especially the coverage by U.S. medical insurance, has not only reduced the company's clinical research costs but also paved the way for the payment process after the product's future launch in the U.S. market.

In the European market,The BrioLife study of BrioVAD has entered the ethical approval stage at clinical trial centers and is scheduled to officially begin enrollment in the first half of 2026.

The company also plans to expand the indication for pediatric heart failure and plans toSubmit a clinical trial application for this indication to the U.S. FDA in the first quarter of 2026.

These layouts indicate that BrioHealth Solutions is building a global product matrix and commercial network covering different regions and patient groups, centered around its core technology platform.

Looking ahead, the success of BrioHealth Solutions is not only a victory of its own technical strength and internationalization strategy, but also a microcosm of the rise of China's high-end medical device industry. With the global promotion of its fully magnetically levitated artificial heart products, andWith the clinical trial progress of next-generation products like BrioVAD, China is expected to transform from a follower to a leader in the field of heart failure treatment, often referred to as "cardiovascular cancer," bringing new hope to millions of patients worldwide.